Pacira BioSciences, Inc. (PCRX)
- Previous Close
31.51 - Open
31.56 - Bid 30.77 x 300
- Ask 30.89 x 100
- Day's Range
30.70 - 31.57 - 52 Week Range
25.33 - 42.63 - Volume
469,245 - Avg. Volume
636,600 - Market Cap (intraday)
1.435B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
20.41 - EPS (TTM)
1.51 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
46.00
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
www.pacira.com711
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PCRX
Performance Overview: PCRX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PCRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PCRX
Valuation Measures
Market Cap
1.43B
Enterprise Value
1.69B
Trailing P/E
20.41
Forward P/E
11.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.42
Price/Book (mrq)
1.61
Enterprise Value/Revenue
2.48
Enterprise Value/EBITDA
9.02
Financial Highlights
Profitability and Income Statement
Profit Margin
10.34%
Return on Assets (ttm)
3.76%
Return on Equity (ttm)
8.49%
Revenue (ttm)
681.75M
Net Income Avi to Common (ttm)
70.47M
Diluted EPS (ttm)
1.51
Balance Sheet and Cash Flow
Total Cash (mrq)
325.89M
Total Debt/Equity (mrq)
65.21%
Levered Free Cash Flow (ttm)
146.28M
Research Analysis: PCRX
Company Insights: PCRX
PCRX does not have Company Insights